Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study

PURPOSE: Sorafenib is currently the only Food and Drug Administration–approved first-line therapy for patients with advanced hepatocellular carcinoma. There are few data examining how sorafenib starting dose may influence patient outcomes and costs. PATIENTS AND METHODS: We retrospectively evaluated...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Reiss, Kim A., Yu, Shun, Mamtani, Ronac, Mehta, Rajni, D’Addeo, Kathryn, Wileyto, E. Paul, Taddei, Tamar H., Kaplan, David E.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2017
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5662845/
https://ncbi.nlm.nih.gov/pubmed/28872925
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.73.8245
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados